Researchers reported that serum extracellular vesicle N-glycomes can classify childhood epilepsy using a non-invasive biomarker approach. The work, published in Engineering, leverages N-glycan profiles on EVs extracted from blood to support diagnosis and disease categorization—addressing a persistent unmet need for biomarkers that reduce reliance on invasive testing or delayed clinical characterization. In a separate line of innovation, imaging and drug delivery approaches continue to expand: UCSF scientists described a membrane-anchoring prodrug strategy intended to conditionally trap therapeutic payloads in tumor tissue, improving retention and efficacy in preclinical models. Together, the two items reflect continued progress toward minimally invasive biomarker discovery and improved localized delivery mechanisms—both practical levers for clinical trial design and patient selection.